Join us on 29 March at 14:00 Brussels time for an online event on what small and medium-sized enterprises (SMEs) contribute to Innovative Medicines Initiative (IMI) projects on health data management, and what they get out of it.
IHI’s States Representatives Group (SRG) has elected Martha Cahill of Ireland as its chair and Jan Skriwanek of Germany as vice chair. Their mandate will run for two years.
ELF now offering screening services to charities and foundations
The IMI-funded European Lead Factory (ELF) hopes to boost charity-funded science by offering its services and assets to charities and foundations around the world.
IMI's ADAPTED project worked to better understand how the presence of a specific gene significantly increases the risk Alzheimer’s disease. The research could open the door to new treatments.
IMI project IMPENTRI’s trial of cancer drug imatinib has shown promising results (lower mortality, shorter ventilation, better outcomes) after 90 days, confirming its benefits in severe COVID-19 cases.
The opportunities and challenges of cancer-on-chip models in immunotherapy
IMI-funded imSAVAR reviewed the state of ‘cancer-on-chip’ technology. While promising, problems with manufacturing to scale make them impractical for the moment.
IMI rare disease research focusses on gene therapy delivery systems, newborn screening, platform trials for neurofibromatosis and finding a cure for fibrodysplasia ossificans progressiva.
IMI health data project EHDEN launched a call for SMEs to apply for training and certification on converting health data from various formats to a common data model. Deadline: 13 April.
